Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 (IPLUS)

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    Seoul National University Bundang Hospital
Updated on 12 February 2022
platelet count
neutrophil count
gastric cancer
systemic chemotherapy
intraperitoneal chemotherapy


Treatment for stage 4 gastric cancer with peritoneal carcinomatosis has been unchanged for decades. The median survival for stage 4 gastric cancer is 9-14 months with systemic chemotherapy. Intraperitoneal chemotherapy in combination with systemic chemotherapy is under many clinical trials mainly in Japan, and are showing promising results.

This is Korea's first clinical trial on Intraperitoneal Paclitaxel with Systemic mFOLFOX6 chemotherapy.

Condition Gastric Cancer Stage IV, Peritoneal Carcinomatosis, Intraperitoneal Paclitaxel, mFOLFOX6
Treatment Paclitaxel, mFOLFOX6 regimen
Clinical Study IdentifierNCT03618758
SponsorSeoul National University Bundang Hospital
Last Modified on12 February 2022


Yes No Not Sure

Inclusion Criteria

Biopsy proven adenocarcinoma of gastric origin, primary or recurrent
Identification of Peritoneal seeding by CT or diagnostic laparoscopy
Patients confirmed to receive mFOLFOX6 on multidisciplinary outpatient clinic
No previous history of chemotherapy or 4week after the last chemotherapy for gastric cancer
Labs adequate for chemotherapy (within 2 weeks of enrollment)
Absolute Neutrophil Count: 1,500/mm
Hemoglobin level: 8.0g/dL
Platelet Count: 10104/mm
AST (GOT), ALT (GPT): 100U/L
Total Bilirubin: 2.0mg/dL
Creatinine Clearance (CCl): 50mL/min
ECOG 0 - 2
Her-2 negative on endoscopic biopsy
Age 20, < 80
Signed Informed consent form

Exclusion Criteria

Patients with other major medical disease or malignant tumors other than gastric cancer
Contraindication to 5-FU, Oxaliplatin, Leukovorin or Paclitaxel
Pregnant, breast-feeding women or with birth plan
Patients refusing treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note